Introduction: Thromboxane A 2 (T ÂA 2 ), activates platelets and causes vasoconstriction. Raised urinary excretion of 11-dehydro-thromboxane B 2 (T Â M), an index of T ÂA 2 formation, is an independent predictor of atherothrombotic events. This is the first study to investigate the genetic determinants of thromboxane levels. Materials and methods: 544 participants in the Hypertension Associated Cardiovascular Disease Sub-study of ASCOT gave urine samples at two separate time-points. T Â M was measured using liquid chromatography/tandem mass spectrometry, expressed as pg mg À1 creatinine to correct for urine concentration. All subjects were genotyped on the CVD50 K chip, a cardiovascular-specific chip with 450 000 SNPs. Usual quality control measures were applied. Linear regression analysis was performed, assuming an additive genetic model, adjusting for the covariates; age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. , P-values range; 0.001-0.009 after adjustment for multiple testing (1000 permutations)). Conditional analyses demonstrated that 3 of these variants, located in introns 1 and 2, were independently associated with T Â M. PPARGC1b encodes peroxisome proliferator-activated receptor gamma coactivator 1b, a transcriptional co-activator previously reported to be associated with type 2 diabetes and obesity. These findings provide a novel insight into the molecular biology of T ÂA 2 biosynthesis, and its role in the causation of heart attacks and strokes. Background: Increased arterial stiffness is associated with a reduced buffering capacity of the large arteries, therefore predisposing the microcirculation to increased flow and pressure pulsatility. Previous data from our group have illustrated a positive relationship between aortic pulse wave velocity and an inverse relationship between wave reflection and retinal artery flow pulsatility. Therefore, the aim of this study was to investigate the macrovascular haemodynamic mechanisms involved in retinal artery flow pulsatility, by manipulation of wave reflection by Glycerol Trinitrate Nitrate administration. Methods: Nine individuals, aged 63±6 years and free from CV acting medication participated in this study. Augmentation index (AIx) was recorded using the SphygmoCor system (Atcor) as a measure of wave reflection. Pulsatility index (PI), a measure of retinal artery flow pulsatility was recorded using doppler ultrasound (GE) and both peripheral and central blood pressure were measured using the Mobilograph system (IEM). All vascular haemodynamic measurements were recored simultaneously at basline and then again at 1, 3, 5, 10 and 15 minutes post GTN administration. Results: The relationship between AIx and PI change from baseline were significantly different at 3 and 5 minutes (P ¼ 0.02 and P ¼ 0.03, respectively). See Figure 1 . Conclusion: This study illustrates a direct inverse relationship between AIx and retinal artery flow pulsatility, suggesting a direct link between large artery haemodynamics and pulsatile flow in the microvasculature. Objectives: To examine the contributions of P1 and AP to age-related increase in central pulse pressure (cPP), and the degree to which this is reversed by nitrovasodilation. Background: cPP can be partitioned into height of the first systolic shoulder (P1), generated by a forward pressure wave and related to arterial stiffness; and augmentation pressure (AP), thought to be influenced by pressure wave reflection and dependent on calibre of muscular arteries. Methods: Using a longitudinal cohort design, cPP, P1, and AP were estimated (SphygmoCor system) in 411 female twins over 10.8 years and using a cross-sectional design with carotid pressure waveforms. In a sub-sample (n ¼ 42), cPP, arterial stiffness (pulse wave velocity, PWV) and arterial diameters (ultrasonography) were measured before and after glyceryl trinitrate (GTN, 400 mg s l À1 ).
Introduction: Thromboxane A 2 (T ÂA 2 ), activates platelets and causes vasoconstriction. Raised urinary excretion of 11-dehydro-thromboxane B 2 (T Â M), an index of T ÂA 2 formation, is an independent predictor of atherothrombotic events. This is the first study to investigate the genetic determinants of thromboxane levels. Materials and methods: 544 participants in the Hypertension Associated Cardiovascular Disease Sub-study of ASCOT gave urine samples at two separate time-points. T Â M was measured using liquid chromatography/tandem mass spectrometry, expressed as pg mg À1 creatinine to correct for urine concentration. All subjects were genotyped on the CVD50 K chip, a cardiovascular-specific chip with 450 000 SNPs. Usual quality control measures were applied. Linear regression analysis was performed, assuming an additive genetic model, adjusting for the covariates; age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, LDL, aspirin and anti-hypertensive regimen. Results and discussion: T Â M levels were significantly lower in patients taking aspirin vs patients not on aspirin (median [interquartile range] 324 [211, 404] vs 716 [460, 913] pg mg À1 , Po0.0001). 21 SNPs spanning 100 kb of the PPARGC1b gene were significantly associated with higher T Â M (b-values range; 123-223 pg mg
À1
, P-values range; 0.001-0.009 after adjustment for multiple testing (1000 permutations)). Conditional analyses demonstrated that 3 of these variants, located in introns 1 and 2, were independently associated with T Â M. PPARGC1b encodes peroxisome proliferator-activated receptor gamma coactivator 1b, a transcriptional co-activator previously reported to be associated with type 2 diabetes and obesity. These findings provide a novel insight into the molecular biology of T ÂA 2 biosynthesis, and its role in the causation of heart attacks and strokes.
Methods: Nine individuals, aged 63±6 years and free from CV acting medication participated in this study. Augmentation index (AIx) was recorded using the SphygmoCor system (Atcor) as a measure of wave reflection. Pulsatility index (PI), a measure of retinal artery flow pulsatility was recorded using doppler ultrasound (GE) and both peripheral and central blood pressure were measured using the Mobilograph system (IEM). All vascular haemodynamic measurements were recored simultaneously at basline and then again at 1, 3, 5, 10 and 15 minutes post GTN administration. Results: The relationship between AIx and PI change from baseline were significantly different at 3 and 5 minutes (P ¼ 0.02 and P ¼ 0.03, respectively). See Figure 1 . Conclusion: This study illustrates a direct inverse relationship between AIx and retinal artery flow pulsatility, suggesting a direct link between large artery haemodynamics and pulsatile flow in the microvasculature.
Cross-sectional and longitudinal 10 year follow-up of Central Pulse Pressure Components and its reversal by Vasodilating Therapy in women
Cecelja M, Jiang B, Spector T and Chowienczyk P St Thomas' Hospital, London, UK Objectives: To examine the contributions of P1 and AP to age-related increase in central pulse pressure (cPP), and the degree to which this is reversed by nitrovasodilation. Background: cPP can be partitioned into height of the first systolic shoulder (P1), generated by a forward pressure wave and related to arterial stiffness; and augmentation pressure (AP), thought to be influenced by pressure wave reflection and dependent on calibre of muscular arteries. Methods: Using a longitudinal cohort design, cPP, P1, and AP were estimated (SphygmoCor system) in 411 female twins over 10.8 years and using a cross-sectional design with carotid pressure waveforms. In a sub-sample (n ¼ 42), cPP, arterial stiffness (pulse wave velocity, PWV) and arterial diameters (ultrasonography) were measured before and after glyceryl trinitrate (GTN, 400 mg s l À1 ).
Results: cPP increased more than peripheral pulse pressure (10.3 and 9.2 mm Hg increase respectively, Po0.0001). In women o50 years at follow-up, AP contributed more to the increase in cPP than P1 (increases of 6.5 ± 6.4 and 4. Results: qPCR replicated the microarray result, showing a 5.9 -fold higher expression in adenomas than normal adrenal, but with 4100-fold variation between patients. Western blots showed the predicted 49kDa protein in 4 pairs of APA and NA. IHC showed the majority of staining to be in zona glomerulosa. In cultures from 2 APAs, 5N-O-T 10 À5 M (K i at cloned GPR61) reduced aldosterone secretion by 50%. Conclusion: GPR61 is in the right place to play a role in physiological or pathological regulation of aldosterone secretion. Bias was detected with both Bland-Altman plot and through quintile analyses (under-/overestimate at low/high levels). ROC curves AUC varied from 0.514 to 0.640 with moderate sensitivity (64-70%) but poor specificity (20-53%). Conclusion: 24 h urinary collection for the measurement of Na excretion remains the preferred tool for assessing population salt intake when compared with methods based on timed spot urine samples. Background: Hypertension is a major problem in sub-Saharan Africa (SSA), with high prevalence rates described in younger adults.
1 Our study documents the prevalence in an elderly rural population of northern Tanzania, often a forgotten part of society at high risk from the consequences of hypertension. Methods: All consenting individuals aged 70 years and over living in 12 randomly-selected villages (from an established Demographic Surveillance Site) underwent three consecutive sitting BP measurements. An average of the last two measurements was taken. Prior diagnosis of, and treatment for, hypertension was recorded. Results: Of 2232 people, 1553 (69.6%) had hypertension (BPX140/90) and 653 (29.3%) had Grade 3 hypertension (BPX180/110). Only 586 (37.7%) hypertensives had been previously diagnosed, 94 (6.1%) were currently treated and 14 (0.9%) were adequately controlled (BP o140/90). Conclusions: Our results approximate to a 'rule of sixths'. 4/6 of the cohort was hypertensive, whilst 2/6 had severe hypertension. Furthermore, 2/6 of hypertensives were previously detected, 1/6 of those previously detected were on treatment and 1/6 of those on treatment were adequately controlled. This is the first large scale prevalence study of hypertension in the elderly in SSA. Our 'rule of sixths' highlights the substantial problem of hypertension in SSA, and the growing number of elderly at risk of hypertensive sequelae due to lack of detection and treatment. When sex-stratified, the association was non significant for men at all times except SBP99. When the sex-SBP interaction was accounted for the association was significant for all time points.
Conclusions: IVSD seems to be positively correlated with SBP. However this relationship may differ between sexes and may only be evident after a certain age has been reached. The role of life course changes in blood pressure and confounding factors (body size, medication etc.) need to be explored. Results: Doctors, nurses and patients were aware that BP measured in the surgery could be a poor indicator of usual BP and this delayed treatment. The rolling average blood pressure from telemetry enabled home monitoring, visible to both the patient and practice, was much more difficult to ignore and prompted changes in self care and treatment. Although patients had different emotional reactions to home monitoring (some saying that focusing on a health risk they normally did not think about increased anxiety, others saying that home monitoring reassured them), many provided examples of using the data to monitor their response to self care changes such as increasing exercise, and medication. They also used the data in healthcare consultations to be more explicit in negotiating what they wanted. Managing telehealth was challenging to practice organisation. Some professionals questioned the value of reaching the target BP on overall cardiovascular risk and reluctance to increase medication and resistance from patients was a theme, although not a major one.
Conclusion:
The quantitative outcome of HITS is currently unknown, but these data suggest that telemetry enabled home BP measurement has a positive effect on management.
4A.1. Ethnic differences in aortic pulse wave velocity occur in the descending aorta independent of blood pressure and may be related to vitamin D Background: Aortic pulse wave velocity (aPWV) is a powerful predictor of cardiovascular events independent of blood pressure (BP). We studied the roles of blood levels of vitamin D as 25(OH)D3 and aldosterone in total and regional aortic stiffness in relation to blood pressure (BP) in a multi-ethnic sample of British men. Methods: Total aPWV was estimated non-invasively by the Arteriograph device (aPWVag) in 198 men with its length measure calibrated by magnetic resonance (MR). PWV over the aortic arch (archPWVmr) and descending aorta (desPWVmr) were measured by MR in a subsample (n ¼ 47). Results: Mean (SE) aPWVag in South Asians (SA) (n ¼ 68, age 55±10 year), at known higher coronary disease (CHD) risk than others, was 0.5(0.2)m/s higher than in African-Caribbeans (AfC, n ¼ 67, 55±10 year), at lowest CHD risk here, and Europeans (n ¼ 63, 57±8 yr), adjusted for age, systolic BP and diabetes (P ¼ 0.01). By MR, desPWVmr in SA was 0.7(0.3) and 0.8(0.3) m s À1 higher than in AfC and Europeans; archPWVmr was not different. SA and AfC had 21(3) and 14(3) nmol l À1 lower mean(SE) 25(OH)D than Europeans (Po0.001), while aldosterone was lowest in AfC in the total and MR samples (Po0.03). Unlike aldosterone, 25(OH)D was negatively correlated with aPWVag adjusted for age and systolic BP, and weakened/ removed cross-ethnic aPWVag differences in regression models. Conclusion: These data suggest aortic stiffness as aPWV parallels CHD risk in ethnic groups, descending aortic but not arch PWV has this feature, serum 25(OH)D is an independent negative correlate of aPWV and may partly explain ethnicity-related differences in aPWV and CHD risk.
4A.2. Systolic inter-arm blood pressure difference is associated with increased cardiovascular and all-cause mortality in hypertension: meta-analysis Introduction: National UK clinical guidelines describe blood pressure (BP) differences o10 mm Hg between arms as normal, and attribute differences 420 mm Hg to peripheral vascular disease. Subjects with a 10-20 mm Hg systolic difference are not discussed, but represent 15% of hypertensive populations. Our UK cohort study associated an inter-arm difference with reduced survival. With access to two further cohorts (from UK and Italy) we were able to undertake meta-analysis of published and unpublished studies to assess the current level of evidence. Methods: Systematic review and meta-analysis. We retrieved studies reporting prospective s urvival outcomes with inter-arm BP difference. Unpublished analyses were sought and included. Primary outcome measure was a hazard ratio (HRs) for cardiovascular or all cause mortality. Results: One published study reported prospective survival data in hypertension. Unpublished new data from this cohort and two unpublished cohorts contributed to the meta-analysis. With systolic interarm BP differences X15 mm Hg, pooled data showed a HR of 2.2 (95% CI 1.1 to 4.5; Po0.05) for all cause mortality and 1.7 (1.1 to 2.7; Po0.05) for cardiovascular mortality. For systolic differences X10 mm Hg HRs were 1.9 (1.0 to 3.6; P ¼ 0.06) and 2.3 (1.2 to 4.5; Po0.05) respectively. Conclusions: Systolic inter-arm BP difference in hypertension is associated with increased cardiovascular and all-cause mortality for a difference X15 mm Hg, and increased cardiovascular mortality for a X10 mm Hg difference. This supports suggestions that inter-arm difference is due to peripheral vascular disease. An inter-arm difference should be considered a marker of elevated cardiovascular risk, and its detection should prompt aggressive lifestyle and risk factor intervention.
5A.1. Cardiovascular and all-cause mortality outcomes among hypertensive patients with moderate renal dysfunction in the ASCOT-LLA, and its extended follow-up Methods: In ASCOT-LLA, 10305 high risk hypertensive patients were randomized to atorvastatin vs placebo (follow-up: 3.2 years). For each of the pre-specified CV and death outcomes, a separate multivariable Cox model was developed. Interaction test was done to evaluate any heterogeneity in the statin effect. In LLA-extended, patients were followed-up for extra 2-years after the LLAclosure. Results: In LLA, among those with no CKD, allocation to atorvastatin vs placebo was associated with a significant reduction in CV-outcomes, and statistically insignificant reduction in deaths. Among those with CKD (n ¼ 2022), statin vs placebo offered similar (albeit statistically insignificant) protection for coronary and death outcomes, but, lesser for stroke (Figure) . However, there was no heterogeneity in the statin effect among those with/ without CKD. In LLA-extended, among those with CKD, allocation to atorvastatin vs placebo was also associated with beneficial (but statistically insignificant) trends in coronary and death outcomes, with lesser protection afforded against stroke. Similar and statistically significant findings were observed among those with no CKD. Again, there was no significant interaction in the statin effect. Conclusions: Among hypertensive patients with CKD, atorvastatin therapy was associated with a reduction in coronary, stroke and death outcomes¸statistically similar to findings seen among those without renal damage. This beneficial trend remained unchanged, 2 years after LLA closure. Recent evidence from observational studies suggests that diets rich in green leafy vegetables may reduce the risk of diabetes (Carter P. et al., BMJ 2010) . This could relate to their high content of dietary nitrate, which has other beneficial effects in humans including blood pressure reduction (Webb A. et al., Hypertension 2008) . In a randomised double blind cross-over study in 8 healthy subjects (4 male, aged 26.5 ± 2.5 years), potassium nitrate (KNO 3 , 24 mmol, in capsule form, nitrate content equivalent to 500 ml beetroot juice in a previous study) administered 1 h before an oral glucose (75 g) tolerance test significantly reduced excursion of the glucose curve and area under the curve (AUC) of the glucose curve by B6% compared to potassium chloride (KCl 24 mmol) (Po0.05, ANOVA). KNO 3 also increased the excursion and AUC of the insulin curve by B22% compared to KCl (P ¼ 0.01). However, no difference in insulin C-peptide was found. On linear regression analysis there was a trend for greater reductions in AUC glucose profiles with KNO 3 to be associated with higher baseline AUC glucose profiles with KCl (r 2 ¼ 0.39, P ¼ 0.05). KNO 3 increased plasma nitrate and nitrite concentrations and exhaled nitric oxide (eNO): at 2 h post-ingestion eNO was 47.2 ± 7.0 ppb, compared to 27.4 ± 4.3 ppb with KCl (Po0.01). KNO 3 also resulted in a trend to a reduced systolic blood pressure of 7.6 ± 3.2 mm Hg compared to KCl 2.5 h after ingestion (P ¼ 0.057). Therefore, dietary nitrate acutely improves postprandial hyperglycaemia, especially in subjects with higher baseline glucose levels.
5A.2. Acute effects of dietary nitrate on glucose handling
Background and methods: Blood pressure (BP) is a heritable and modifiable determinant of cardiovascular disease. We conducted a genome-wide association study testing 2.5 million directly genotyped, or imputed single nucleotide polymorphisms (SNPs) for association with systolic and diastolic BP in B70 000 individuals of European ancestry with staged validation in an additional B130 000 people of European ancestry. We followed up these findings in 75 000 people of non-European ancestry and evaluated their impact on cardiovascular risk.
Results: This approach identified 29 genome-wide significant independent SNPs at 28 loci at Po5 Â 10 À9 in meta-analysis. Sixteen of these 29 loci are novel and lie in, or near, MOV10, SLC4A7, MECOM, SLC39A8, GUCY1A3-GUCY1B3, NPR3-C5orf23, EBF1, HFE, BAT2-BAT5, PLCE1, ADM, FLJ32810-TMEM133, FES, GOSR2, JAG1, and GNAS-EDN3. Each variant exhibited small effects on BP (o1 mm Hg for SBP and o0.5 mm Hg DBP per risk allele) and the effects were mostly concordant across analyses of SBP, DBP, and hypertension. In addition, we evaluated these 29 BP variants using a European ancestryderived genetic risk score in several non-European ancestry cohorts. We found an association with SBP P ¼ 7. Hypertension and its complications are increasingly common in Nigeria, where malaria is hyper-endemic. We established a birth cohort in Ibadan to assess the impact of maternal malaria on blood pressure (BP) in Nigerian infants over their first year. Healthy pregnant women had regular blood films for malaria parasites through to delivery. Growth and BP were measured on 318 babies, all followed from birth to 3 and 12 months. Babies exposed to maternal malaria were shorter, smaller and thinner at birth and remained smaller at 1 year, most marked in boys, whose systolic (S)BP adjusted for weight at 3 and 12 months was higher than those not exposed (at 3 months þ 0.6 mm Hg kg À1 , 95% CI 0-1.2, P ¼ 0.04). Change in SBP over the first year was greater in boys than girls (20.9 vs 15.7 mm Hg P ¼ 0.002) but greater in girls exposed to maternal malaria (18.7 vs 12.7 mm Hg, 95% CI 1-11, P ¼ 0.02). 11% of boys (4twice expected) had a SBP X95th percentile (hypertensive, US criteria) of whom 68% had maternal malaria exposure. On regression analysis, gender, maternal malaria exposure and weight change all independently increased change in BP to 1 year. Maternal malaria exposure had a greater adverse effect on growth in boys than girls with boys having higher than expected incidence of hypertension at one year; girls had a greater increase in BP. Intrauterine exposure to malaria has important gender-dependent effects on growth and infant BP and may contribute to the global burden of hypertension.
5A.6. Both amiloride and nebivolol have a more favourable effect on glucose tolerance than hydrochlorothiazide in the treatment of essential hypertension-results of a double blind, placebo controlled, randomised cross over study Stears AJ 1, 2 The dose of thiazide diuretics is limited, and combination with â-blockade discouraged, because of a perceived risk of diabetes. We tested whether the rise in 2-hour glucose on hydrochlorothiazide (HCZ) is avoided by switching to amiloride or by combining HCZ with nebivolol. 37 patients with essential hypertension, mean age 64, participated in a double-blind, cross-over study. They received, in random order, 4 weeks once-daily treatment with HCZ 25-50 mg, nebivolol 5-10 mg, combination (HCZ 25-50 mg þ nebivolol 5-10 mg), amiloride (10-20 mg) and placebo. Each drug was forcetitrated at 2 weeks and separated by a 4-week placebo washout. At each visit, we measured BP and electrolytes, and performed a 75 g OGTT. Data (mean (s.d.)) was analysed by repeated measures between drugs. For similar BP reductions, there were opposing changes in 2-hour glucose between the two diuretics and between HCZ and nebivolol (both Po0.0001). There was a negative correlation between delta potassium and delta 2-hour glucose (r ¼ À0.28, Po0.0001). 30 0 insulin was not significantly affected. We conclude that the solution to HCZ-induced hyperglycaemia is not to reduce the dose but to switch to or combine with amiloride. This should be confirmed by the BHS's BHF-funded PATHWAY-3 trial. 
